Drug Trial Radar · NCT07292168
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Dec 2, 2025
Primary completion
Jan 1, 2027
Study completion Jan 1, 2027
Sponsor
- Lead sponsor
- Kidney Cancer Research BureauAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
One of the most relevant targets in the field of novel targeted anticancer therapy is the family of receptors to fibroblast growth factor receptors (FGFRs). FGFR1 is the main representative of the FGFR family. The goal of this clinical trial is to learn if monoclonal anti-FGFR1 antibody (OM-RCA-01) works to treat metastatic cancers expressing FGFR1. It will also learn about the safety of drug OM-RCA-01. The main questions it aims to answer are: 1. What medical problems do participants have when receiving drug OM-RCA-01? 2. What dose of the drug should patients receive in the next studies? 3. Does tumor growth slow down in patients receiving OM-RCA-01? All patients in this study will receive the antibody treatment. The drug will be given through a vein (by IV infusion) every two weeks, for as long as the disease remains under control and the treatment is well tolerated.
Conditions
- Renal Cell Carcinoma Metastatic
- Prostate Cancer Metastatic
- Non-small Cell Lung Cancer Metastatic
- Breast Cancer Metastatic
- Head & Neck Cancer
Interventions
humanized monoclonal anti-FGFR1 antibody OM-RCA-01Biological
OM-RCA-01, solution for infusion, 25 mg/mL; 50 mg (dose level 1), 100 mg (dose level 2), 200 mg (dose level 3), 400 mg (dose level 4), 600 mg (dose level 5) intravenously, every 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary endpoint in the phase 1b studyTime frame: 6 months
- Primary endpoint in the phase 2 studyTime frame: 12 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Republican Dispensary of Tatarstan
Kazan', Russia · Active not recruiting
A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center
Krasnoyarsk, Russia · Recruiting
Hadassah Medical
Moscow, Russia · Recruiting
I.P. Pavlov First Saint Petersburg State Medical University
Saint Petersburg, Russia · Recruiting
Republican Clinical Oncology Dispensary
Ufa, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.